KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Revenue (2019 - 2025)

Esperion Therapeutics' Revenue history spans 7 years, with the latest figure at $168.4 million for Q4 2025.

  • For Q4 2025, Revenue rose 143.73% year-over-year to $168.4 million; the TTM value through Dec 2025 reached $403.1 million, up 21.31%, while the annual FY2025 figure was $403.1 million, 21.31% up from the prior year.
  • Revenue reached $168.4 million in Q4 2025 per ESPR's latest filing, up from $87.3 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $168.4 million in Q4 2025 to a low of $8.0 million in Q1 2021.
  • Average Revenue over 5 years is $50.3 million, with a median of $33.1 million recorded in 2023.
  • Peak YoY movement for Revenue: plummeted 80.84% in 2021, then soared 466.14% in 2024.
  • A 5-year view of Revenue shows it stood at $15.4 million in 2021, then rose by 22.19% to $18.8 million in 2022, then soared by 71.38% to $32.2 million in 2023, then surged by 114.3% to $69.1 million in 2024, then surged by 143.73% to $168.4 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Revenue are $168.4 million (Q4 2025), $87.3 million (Q3 2025), and $82.4 million (Q2 2025).